ACS Prognosis via Platelet Function and H-FABP Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remain at risk of recurrent ACS due to poor response to clopidogrel, and current methods fail to accurately identify those at higher risk for future adverse events, leading to potential increased bleeding from indiscriminate use of more potent antiplatelet agents.
Innovation Solution
Combining platelet function testing with heart fatty acid-binding protein (H-FABP) measurements before PCI to stratify patients' risk, using the VerifyNow test for platelet activity and H-FABP levels to identify those at greater risk of future adverse events, allowing for tailored antiplatelet therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If more potent antiplatelet agents are used indiscriminately to prevent recurrent ACS, then the prevention of recurrent ACS events is improved, but the rate of bleeding increases
Solution Approach 1:
The patent applies local quality by tailoring the antiplatelet therapy to individual patients based on their platelet function test results and H-FABP levels. Instead of uniform treatment, patients are stratified into different risk categories (low, intermediate, high) and receive appropriately intensified therapy only when needed, thereby preventing recurrent ACS in high-risk patients while avoiding unnecessary bleeding in low-risk patients.
Solution Approach 2:
The patent changes the parameter of platelet inhibition intensity based on measured platelet function (PRU values) and biomarker levels. By monitoring these parameters and adjusting therapy accordingly, the system optimizes the balance between preventing recurrent ACS and minimizing bleeding risk, moving from fixed-dose therapy to dynamic, parameter-based treatment adjustment.
2Measurement precision
If platelet function testing and H-FABP measurement are combined to precisely identify high-risk patients, then the accuracy of risk stratification is improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent performs platelet function testing and H-FABP measurement before PCI procedure as preliminary actions. This advance testing allows risk stratification to be established prior to intervention, enabling proactive treatment planning without adding complexity during the critical PCI procedure itself.
Solution Approach 2:
The patent introduces H-FABP as an intermediary biomarker that provides additional prognostic information beyond platelet function testing alone. This intermediary marker helps refine risk stratification by capturing myocardial injury information that complements the platelet activity data, creating a more comprehensive risk assessment framework.
Data Source
Figure 1
AI summary
The current invention provides an improved method for more precise prognosis of patients having acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The combination of performing a platelet function test prior to PCI and measuring Heart Fatty Acid Binding Protein (H-FABP) prior to PCI can more precisely risk-stratify the patients and has the potential to allow selection of patients who may benefit from more intense platelet inhibition.